BTIG Maintains Buy on Climb Bio, Raises Price Target to $19
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $8 to $19.
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $8 to $19.